Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Stock analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Schrödinger in a research report issued to clients and investors on Wednesday, February 26th. Leerink ...

Equities research analysts at Leerink Partnrs issued their FY2026 EPS estimates for Kura Oncology in a note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst J. Chang ...

The presentation will be accessible via live webcast here. A webcast replay will be available for two weeks following the presentation in the Events section of NeuroPace’s Investor website at ...

Leerink analyst Faisal Khurshid downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a price target of $2, down from ...

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside ...

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet ...

For those investors interested in scheduling a one-on-one meeting with the Remix management team, please contact your Leerink representative.

Molecular Partners will present at TD Cowen and Leerink healthcare conferences and host a financial results call on March 7. Molecular Partners AG, a clinical-stage biotech company focused on ...

Tuesday, Leerink Partners began coverage on Maze Therapeutics shares (NASDAQ:MAZE), currently trading at $10.82 with a market capitalization of $525 million, assigning an Outperform rating and a price ...